Table 1.

Basic information of the patients.

Variables	N (%)
Gender Female Male	310 (78) 87 (22)
Mean age Age > 50 Age ≤ 50	36.5 (± 9.5) 36 (9) 350 (88)
Province of residence Isfahan Tehran Guilan Mazandaran Qazvin Khuzestan East Azerbaijan Fars Kermanshah	108 (27) 74 (19) 40 (10) 38 (10) 35 (9) 34 (9) 33 (8) 27 (7) 8 (2)
MS type RR SP CIS PP	298 (75) 32 (8.1) 22 (5.5) 15 (3.8)
Median EDSS (IQR) EDSS ≤ 3 EDSS > 3	1.5 (1–3) 279 (70) 118 (30)
MS drug No drug Injectable (Glatiramer acetate, Interferon beta-1a, Interferon beta-1b) Dimethyl fumarate Teriflunomide Fingolimod Natalizumab Rituximab Ocrelizumab Azathioprine	18 (4.5) 113 (28.4) 41 (10.3) 18 (4.5) 36 (9.1) 6 (1.5) 139 (35.0) 3 (0.8) 3 (0.8)
Steroid in the last three months before covid-19 infection Negative Positive	364 (92) 33 (8)
Supplementary drugs Vitamin D Vitamin C Zinc NSAID ACE inhibitors	339 (85) 111 (28) 71 (18) 8 (2) 2 (0.5)
Chronic comorbidities Hypertension Diabetes mellitus Asthma Chronic obstructive pulmonary disease (COPD) Respiratory allergy Previous pneumonia Cancer Pregnancy Others	19 (5) 14 (4) 5 (1) 1 (0.3) 8 (2) 4 (1) 1 (0.3) 1 (0.3) 40 (10)

N: number, SD: standard deviation, RR: relapsing- remitting, SP: secondary progressive, CIS: clinically isolated syndrome, PP: primary progressive, EDSS: Expanded Disability Status Scale, NSAID: non-steroidal anti-inflammatory drugs, ACE: angiotensin-converting enzyme